The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
Abstract
Purpose: To shorten the study conduct timeline of pediatric phase I oncology trials by employing a novel trial design. Methods: A comparison of the traditional 3 + 3 patients per cohort, phase I trial design with a novel, rolling six design was performed by using discrete event simulation. The rolling six design allows for accrual of two to six patients concurrently onto a dose level based on the number of patients currently enrolled and evaluable, the number experiencing dose-limiting toxicity (DLT), and the number still at risk of developing a DLT. Clinical trial simulations (n = 1,000) were based on historical data and were performed using SAS 9.1.3 (SAS Institute, Cary, NC). Study timelines and patient numbers were determined for each design, and safety was assessed as a function of the number of DLTs observed. Results: In twelve completed historical studies, the median time to study completion was 452 days (range, 220 to 606 days); number of evaluable participants enrolled was 22 (range, 11 to 33), and DLTs occurring per study was three (range, 0 to 5). In 1,000 study simulations, in which the average time to new patient accrual was 10 days, the average ± standard deviation (SD) time to study completion was 294 ± 75 days for the rolling six design versus 350 ± 84 days for the 3 + 3 design, whereas the number of DLTs per study was the same (average ± SD, 3.3 ± 1.1 v 3.2 ± 1.1 for the rolling six and 3 + 3 designs, respectively). Conclusion: The rolling six design may significantly decrease the duration of pediatric phase I studies without increasing the risk of toxicity. The design will be tested prospectively in upcoming Children's Oncology Group phase I trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 472
Connelly, L. G., & Bair, A. E. (2004) · Academic Emergency Medicine · doi:10.1197/j.aem.2004.08.021 · Cited by 209
Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents
Rosner, G. L., Stadler, W., & Ratain, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.126 · Cited by 201
Möller, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140909 · Cited by 156
Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency
Lee, D. P., Skolnik, J. M., & Adamson, P. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1568 · Cited by 127
Self-citationShechter, S. M., Bryce, C. L., Alagöz, O., Kreke, J. E., Stahl, J. E., Schaefer, A. J., Angus, D. C., & Roberts, M. S. (2005) · Medical Decision Making · doi:10.1177/0272989x04268956 · Cited by 122
New designs for phase 2 clinical trials
Estey, E. H., & Thall, P. F. (2003) · Blood · doi:10.1182/blood-2002-09-2937 · Cited by 114
Operating characteristics of the standard phase I clinical trial design
Reiner, E., Paoletti, X., & O'Quigley, J. (1999) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(98)00095-4 · Cited by 104
Conduct of phase I trials in children with cancer.
Smith, M. A., Bernstein, M. L., Bleyer, W. A., Borsi, J. D., Ho, P., Lewis, I. J., Pearson, A., Pein, F. J. L., Pratt, C. B., Reaman, G. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.966 · Cited by 93
Cited by
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Self-citationvon Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614
Laetsch, T. W., DuBois, S. G., Mascarenhas, L., Turpin, B., Federman, N., Albert, C. M., Nagasubramanian, R., Davis, J. L., Rudzinski, E., Feraco, A. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30119-0 · Cited by 552
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Issa, G. C., Aldoss, I., DiPersio, J., Cuglievan, B., Stone, R., Arellano, M., Thirman, M. J., Patel, M. R., Dickens, D. S., Shenoy, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05812-3 · Cited by 507
Metadata
- Authors
- Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D., & Adamson, P. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-10
- Volume
- 26
- Issue
- 2
- Pages
- 190-195
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104438003
- Cited by
- 282
- References
- 13
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. https://app.cochat.ai/papers/10.1200/jco.2007.12.7712
- The paper
- Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D., & Adamson, P. C. (2008). Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.12.7712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.